MDSpire NewsFDA Approves Low-Estrogen Contraceptive Patch

✅ FDA Approval / Regulatory Action

The FDA approved the norelgestromin/ethinyl estradiol transdermal system (Gwyn Lo) for pregnancy prevention in women with BMI below 30 kg/m² who are candidates for combined hormonal contraception. Approval was supported by Phase 3 efficacy, bleeding-profile, safety, and patch-adhesion data.

Clinical Considerations

• Phase 3 investigators reported a Pearl Index of 4.14 among women aged 18-35 years in the efficacy-evaluable population.
• Complete patch detachment occurred in 1.3% of nearly 40,000 patches applied during the year-long study.
• Unscheduled bleeding or spotting declined from 34.5% in cycle 1 to 20.0% by cycle 13.
• The patch delivers 220 mcg/day norelgestromin and 20 mcg/day ethinyl estradiol with once-weekly application.

Practice Applications

• Recognize a newly available low-estrogen transdermal contraceptive option.
• Review BMI eligibility criteria before prescribing.
• Monitor counseling discussions regarding patch adherence and weekly administration.
• Interpret contraindications consistently with other combined hormonal contraceptives.